Lu P, Alterman M A, Chaurasia C S, Bambal R B, Hanzlik R P
Department of Medicinal Chemistry, University of Kansas, Lawrence 66045-2506, USA.
Arch Biochem Biophys. 1997 Jan 1;337(1):1-7. doi: 10.1006/abbi.1996.9768.
A series of omega-substituted fatty acids with potential heme-coordinating groups was synthesized as inhibitors of lauric acid omega-hydroxylation. The compounds were evaluated using liver microsomes from clofibrate (CF)-induced rats and an engineered expressed CYP4A1-derived fusion protein called f4A1. omega-Imidazolyl-decanoic acid (compound 11) and omega-aminolauric acid (compound 7) were potent Type II ligands and potent inhibitors of lauric acid omega-hydroxylation in both CF-microsomes and f4A1. Replacing their terminal amino or imidazolyl groups with other potential iron-binding groups such as omega-methylsulfinyl-, omega-cyano-, omega-azido-, or omega-formamido all greatly reduced their potency as inhibitors of omega-hydroxylation and their affinity for cytochrome P450 as measured by Ks values. In CF-microsomes, inhibition of (omega-1)-hydroxylation of lauric acid by a homologous series of omega-imidazolyl-alkanoic acids varied only 2-fold but in the same incubations inhibition of omega-hydroxylation increased 22-fold upon going from C-8 to C-12. A similar dependence of binding affinity and inhibitory potency on chain length was also seen in the f4A1 system. In contrast, chain length had little effect on activity among n-alkylamines or N-alkylimidazoles lacking a carboxyl or other polar functional group, suggesting that 7, 11, and related bifunctional compounds interact with CYP4A1 in CF-microsomes and with f4A1 in a specific bidentate fashion. Imidazoles containing phenyl, benzyl, or phenylethyl substituents at N-1 interact less strongly than related N-alkyl-imidazoles of similar carbon number and hydrophobicity, suggesting that the steric bulk and/or rigidity of the phenyl ring is not well accommodated in the active site.
合成了一系列带有潜在血红素配位基团的ω-取代脂肪酸,作为月桂酸ω-羟化作用的抑制剂。使用来自氯贝丁酯(CF)诱导大鼠的肝微粒体和一种名为f4A1的工程表达的CYP4A1衍生融合蛋白对这些化合物进行了评估。ω-咪唑基癸酸(化合物11)和ω-氨基月桂酸(化合物7)是强效的II型配体,并且在CF-微粒体和f4A1中都是月桂酸ω-羟化作用的强效抑制剂。用其他潜在的铁结合基团如ω-甲亚磺酰基、ω-氰基、ω-叠氮基或ω-甲酰胺基取代它们的末端氨基或咪唑基,都极大地降低了它们作为ω-羟化作用抑制剂的效力以及通过Ks值测量的它们对细胞色素P450的亲和力。在CF-微粒体中,一系列ω-咪唑基链烷酸对月桂酸(ω-1)-羟化作用的抑制仅相差2倍,但在相同孵育条件下,从C-8到C-12,ω-羟化作用的抑制增加了22倍。在f4A1系统中也观察到了结合亲和力和抑制效力对链长的类似依赖性。相比之下,链长对缺乏羧基或其他极性官能团的正烷基胺或N-烷基咪唑的活性影响很小,这表明7、11和相关的双功能化合物以特定的双齿方式与CF-微粒体中的CYP4A1以及与f4A1相互作用。在N-1位含有苯基、苄基或苯乙基取代基的咪唑与具有相似碳原子数和疏水性的相关N-烷基咪唑相比,相互作用较弱,这表明苯环的空间位阻和/或刚性在活性位点中不能很好地容纳。